S&P 500 Industrials Sector SEC Filings — March 26, 2026

26-03-2026

aTyr Pharma, Inc. filed DEFA14A additional proxy materials for its 2026 Annual Meeting of Stockholders on May 11, 2026, at 9:00 a.m. PT, seeking approval for electing three Class II directors (Eric Benevich, Timothy P. Coughlin, Jane A. Gross, Ph.D.), ratifying Ernst & Young LLP as auditors for FY 2026, advisory approval of executive compensation, amending the 2015 Stock Option and Incentive Plan, and increasing authorized common shares from 170,000,000 to 340,000,000. The Board recommends voting FOR all proposals. Proxy materials are available online at https://web.viewproxy.com/atyr/2026, with paper requests due by April 28, 2026.

• ·Meeting location: 10240 Sorrento Valley Road, San Diego, CA 92121
• ·Directors to serve until 2029 annual meeting or successors elected

26-03-2026

Teradata Corporation's 2026 proxy statement outlines the virtual annual meeting on May 14, 2026, seeking approval to elect Stephen McMillan, Melissa B. Fisher, and Kimberly K. Nelson as Class I directors, an advisory vote on executive compensation, the amended and restated Teradata 2023 Stock Incentive Plan, and ratification of the independent auditor for 2026. Daniel R. Fishback is retiring, reducing the board from 10 to 9 members post-meeting, with a new Class II director to be appointed by August 1, 2026, per a February 10, 2026 Cooperation Agreement with Lynrock Lake Partners. Governance highlights include a 90% independent board, 40% gender diversity, and 20% ethnic minority representation, alongside average tenure of 8 years.

• ·Record date: March 19, 2026
• ·Annual meeting: May 14, 2026 at 8:00 a.m. Pacific Time (virtual at www.virtualshareholdermeeting.com/TDC2026)
• ·Ms. Fisher elected to Board effective March 1, 2026
• ·One current Class II director not to be renominated at 2027 annual meeting
• ·Board committees (Audit, Compensation, Governance) fully independent

26-03-2026

Tradeweb Markets Inc. has issued its DEF 14A Proxy Statement for the 2026 virtual Annual Meeting of Stockholders on May 19, 2026, seeking approval for electing three Class I directors, ratifying Deloitte & Touche LLP as independent auditors for FY 2026, an advisory vote on named executive officer compensation, and two amendments to the Certificate of Incorporation (Exculpation Amendment and Federal Forum Selection Amendment). The Board unanimously recommends voting 'FOR' all proposals, highlighting strong board expertise in capital markets (11/11 directors), electronic trading (8/11), and other areas, with 55% independence and average tenure of 4.4 years. Executive compensation emphasizes performance alignment, with CEO target compensation 79% in equity and 95% at-risk, and non-CEO NEOs at 60% equity and 93% at-risk.

• ·Record date for stockholders: March 20, 2026
• ·Meeting format: Virtual at www.virtualshareholdermeeting.com/TW2026
• ·Proxy materials available on or about March 26, 2026 via www.proxyvote.com
• ·Annual Report for year ended December 31, 2025 filed February 5, 2026

26-03-2026

BARK, Inc. held its 2025 Annual Meeting of Stockholders on March 25, 2026, where shareholders elected Betsy McLaughlin (85,410,450 votes for) and Henrik Werdelin (90,493,977 votes for) as Class A directors, ratified Deloitte & Touche LLP as the independent auditor (99,180,657 votes for), and approved an amendment authorizing a reverse stock split (83,955,161 votes for vs. 57,254,747 against). On an advisory basis, executive compensation was approved (60,101,236 for vs. 14,022,631 against), reflecting some shareholder opposition. The Board approved a 1-for-20 reverse stock split effective April 1, 2026, with trading on a split-adjusted basis beginning at market open.

• ·Annual Meeting held on March 25, 2026; proxy statement filed February 12, 2026
• ·Reverse stock split at 1:20 ratio; every 20 shares converted to 1 share; no fractional shares, cash in lieu based on NYSE closing price prior to April 1, 2026 effective time
• ·Proportionate adjustments to equity awards, incentive plans, exercise prices
• ·Fiscal year ending March 31, 2026

26-03-2026

Rhythm Pharmaceuticals, Inc. announced that the EMA's CHMP has adopted a positive opinion recommending expansion of the IMCIVREE (setmelanotide) marketing authorization to include treatment of obesity and control of hunger in adults and children aged 4 years and above with acquired hypothalamic obesity (HO) due to hypothalamic injury or impairment. The opinion will be reviewed by the European Commission, with a final decision anticipated in Q2 2026. This regulatory milestone represents a potential significant expansion of the product's label in the EU.

• ·Filing date and event date: March 26, 2026
• ·CHMP positive opinion not deemed 'filed' under Section 18 of the Exchange Act
• ·Press release furnished as Exhibit 99.1

26-03-2026

Acumen Pharmaceuticals reported a widened net loss of $121,335 thousand for the year ended December 31, 2025, up 19% from $102,329 thousand in 2024, driven by a 12% increase in R&D expenses to $104,885 thousand and a 79% drop in total other income to $2,497 thousand, though G&A expenses declined 6% to $18,947 thousand. Total operating expenses rose 9% to $123,832 thousand, with net cash used in operating activities increasing to $115,538 thousand from $86,215 thousand. Cash and cash equivalents improved to $53,989 thousand by year-end, supported by $133,933 thousand net cash from investing activities, while total assets fell to $122,833 thousand from $238,992 thousand and stockholders' equity decreased to $70,430 thousand from $181,816 thousand.

• ·Net cash provided by investing activities increased to $133,933 thousand in 2025 from $48,027 thousand in 2024.
• ·Marketable securities, short-term decreased to $62,876 thousand as of Dec 31, 2025 from $135,930 thousand as of Dec 31, 2024.
• ·Debt, short-term increased to $8,765 thousand as of Dec 31, 2025 from $0.
• ·Stock-based compensation expense rose slightly to $9,852 thousand in 2025 from $9,635 thousand in 2024.
• ·Net loss per common share, basic and diluted was $(2.00) in 2025 vs $(1.71) in 2024.

26-03-2026

On March 26, 2026, The First Bancorp, Inc. (FNLC) filed an 8-K under Item 8.01 announcing the declaration of a cash dividend, as detailed in the press release furnished as Exhibit 99.1. The filing was signed by Richard M. Elder, Executive Vice President & Chief Financial Officer. No specific dividend amount or payment details were provided in the filing body.

• ·Filing Type: 8-K, Item 8.01 Other Events
• ·Date of earliest event reported: March 26, 2026
• ·Registrant state of incorporation: Maine
• ·Commission file number: 0-26589
• ·IRS employer identification no.: 01-0404322
• ·Principal executive offices: 223 Main Street, Damariscotta, Maine 04543
• ·Telephone: (207) 563-3195
• ·Trading symbol: FNLC

26-03-2026

Paychex Inc reported robust Q3 FY2026 revenue growth of 19.8% YoY to $1,808.9M, with Management Solutions up 23.0% to $1,354.6M and PEO and Insurance Solutions up 8.8% to $397.5M, driving operating income up 14.5% to $792.0M and net income up 7.9% to $560.3M. However, for the nine months ended February 28, 2026, while total revenue increased 18.4% YoY to $4,906.5M, net income declined 1.5% to $1,339.5M and diluted EPS fell 1.3% to $3.71, impacted by sharply higher selling, general, and administrative expenses (up 42.7% in Q3) and interest expense. Balance sheet strengthened with total assets up 5.7% to $17,511.4M, but stockholders' equity decreased to $4,013.6M after $361.6M in share repurchases.

• ·Interest expense Q3 FY2026: $68.1M vs $22.6M prior year (up 201%)
• ·Operating cash flow nine months FY2026: $1,975.8M vs $1,557.1M prior year (up 26.9%)
• ·Funds held for clients as of Feb 28, 2026: $5,610.9M vs $4,813.3M at May 31, 2025
• ·Cash dividends declared nine months FY2026: $1,165.0M ($3.24 per share)

26-03-2026

Reliance Global Group, Inc. (trading as EZRA on Nasdaq Capital Market) filed Amendment No. 1 to its Form 10-K for the fiscal year ended December 31, 2025, on March 26, 2026, to add the omitted Compensation Recovery Policy dated November 13, 2023, as Exhibit 97.1 and include current-dated CEO and CFO certifications under Section 302 of Sarbanes-Oxley. This is an exhibits-only filing with no changes to financial statements or other disclosures from the original 10-K filed March 10, 2026. As of March 10, 2026, the company had 21,253,013 shares of common stock outstanding (par value $0.086), with non-affiliate market value of approximately $5.3 million based on the June 30, 2025 closing price of $1.87.

• ·Company classified as smaller reporting company and non-accelerated filer.
• ·Securities: Common Stock (EZRA), Series A Warrants (EZRAW) on Nasdaq Capital Market.

26-03-2026

Global AI, Inc. reported the resignation of its independent registered public accounting firm, Chaikin, Cohen, Rubin & Co. (CCR), effective March 10, 2026, due to CCR's internal considerations unrelated to the Company, with the Board accepting it on March 25, 2026. CCR's audit report for the fiscal year ended December 31, 2024, included an explanatory paragraph regarding the Company's ability to continue as a going concern but contained no adverse opinions, disagreements, or reportable events. The Board engaged Barzily & Co. as the new independent auditor effective March 18, 2026, for the fiscal year ended December 31, 2025 and subsequent periods, with no prior consultations on accounting or auditing matters.

• ·CCR served as the Company's auditor since June 1, 2025.
• ·The Company is incorporated in Nevada (Commission File Number: 333-163439; IRS EIN: 26-4170100).
• ·Principal executive offices: 110 Front Street, Suite 300, Jupiter, FL 33477.

26-03-2026

Collaboration revenue grew 20% YoY to $2,854 thousand amid a post-IPO ramp-up, with interest income rising 40% to $16,933 thousand. However, R&D expenses more than doubled to $136,806 thousand and total operating expenses surged 104% to $163,215 thousand, driving net loss to widen 128% to $143,443 thousand; cash and equivalents dropped sharply to $101,578 thousand from $325,892 thousand, with net cash use of $224,314 thousand.

• ·Net cash provided by financing activities fell to $2,441 thousand in 2025 from $418,910 thousand in 2024 post-IPO.
• ·Total assets decreased to $353,772 thousand from $481,719 thousand.
• ·Stock-based compensation expense rose to $10,332 thousand from $6,004 thousand.
• ·Weighted-average common shares outstanding increased to 53,852,752 from 13,682,326.

26-03-2026

Quantum Biopharma Ltd. filed its 20-F Annual Report on March 26, 2026, disclosing a successful defense in a wrongful dismissal arbitration initially claiming $30.2 million, which was dismissed in 2022 with costs awarded to the Company. However, multiple ongoing court proceedings persist related to share cancellations, indemnification claims, and U.S. enforcement of arbitration awards. The report highlights significant risks including potential share dilution from future issuances, PFIC tax status adversely affecting U.S. holders, commercialization challenges for Product Candidates, and exposures tied to SOL cryptocurrency such as regulatory scrutiny, variable staking returns, and network vulnerabilities.

• ·Arbitration dismissed in 2022 with costs awarded to the Company.
• ·SIMD-228 proposal to transition SOL to dynamic inflation model failed in 2025.
• ·Ongoing risks from Solana core developers' ability to amend network source code.

26-03-2026

Evogene Ltd. reported FY2025 revenues of $3,853 thousand, a 31% YoY decline from $5,577 thousand in FY2024, driven by drops in Agriculture (down 53% to $1,374 thousand) and Human Health (to $0), with Industrial Applications flat at $2,168 thousand; this led to a gross loss of $241 thousand versus a $3,197 thousand profit, due to $2,180 thousand inventory impairment. Operating loss narrowed 25% YoY to $14,034 thousand from $18,804 thousand amid cost reductions in R&D and G&A, but all segments remained deeply unprofitable. Net loss improved to $7,827 thousand from $18,054 thousand, boosted by $5,672 thousand income from discontinued operations, though management flags substantial going concern doubts and history of losses.

• ·Substantial doubt about going concern for one year from March 26, 2026 filing date.
• ·Classified as PFIC for U.S. tax purposes in 2025, risk of 2026 classification.
• ·FY2025 R&D expenses $7,994 thousand (down from $12,511 thousand in 2024).
• ·All segments reported operating losses in FY2025: Agriculture $(4,097) thousand, Industrial Applications $(3,540) thousand, Human Health $(2,653) thousand, Unallocated $(3,744) thousand.

26-03-2026

The Vanguard Group Inc. filed a Schedule 13G/A amendment on March 26, 2026, disclosing an internal realignment on January 12, 2026, pursuant to SEC Release No. 34-39538, under which certain subsidiaries will report beneficial ownership of General Electric Co. common stock separately on a disaggregated basis. Vanguard certifies that it holds these securities passively in the ordinary course of business, with no intent to influence control, and no single other person's interest exceeds 5%. No changes in aggregate ownership levels or control intentions are indicated.

• ·Filing relies on Rule 13d-1(b) for passive investors.
• ·General Electric Co. address: 1 Neumann Way, Cincinnati, OH 45215.
• ·Vanguard subsidiaries pursue same investment strategies post-realignment.

26-03-2026

Eastern Bankshares, Inc. (EBC) issued a DEFA14A notice for its Annual Meeting of Shareholders on May 18, 2026, for shareholders of record as of March 13, 2026. Proposals include electing six directors (Luis A. Borgen, Diane S. Hessan, Leon A. Palandjian, Robert F. Rivers, Cathleen A. Schmidt, Michael J. Sullivan), an advisory vote to approve named executive officer compensation, and ratification of Ernst & Young LLP as independent auditors for fiscal 2026. The Board recommends voting 'FOR' all proposals; proxy materials including the FY 2025 Annual Report and 2026 Proxy Statement are available at www.proxydocs.com/EBC.

• ·ESOP/401(k) voting instructions deadline: May 13, 2026 at 11:59 p.m. Eastern Time
• ·Proxy materials available at www.proxydocs.com/EBC
• ·Filing date: March 26, 2026

26-03-2026

The 20-F annual report filing for Global-E Online Ltd. (GLBE), dated March 26, 2026, includes definitions of key performance indicators and non-GAAP financial measures used throughout the report. These include Gross Merchandise Value (GMV), Adjusted EBITDA and margin, Non-GAAP Gross Profit and margin, Net Dollar Retention Rate, Gross Dollar Retention Rate (GDR), Free Cash Flow, Non-GAAP net profit, and Non-GAAP net profit per share. No specific financial figures, period-over-period comparisons, or performance data are provided in this section.

26-03-2026

Farmers & Merchants Bancshares, Inc. reported net income of $5,766 thousand for 2025, up 34.8% YoY from $4,278 thousand, supported by net interest income growth of 17.0% to $24,390 thousand from higher loan volumes (+10.7% average balance to $617,249 thousand) and improved net interest margin (3.02% vs 2.68%). However, total deposits declined 5.0% to $720,459 thousand, average taxable securities balances fell 20.6% to $145,331 thousand with interest income down 33.4%, and provision for credit losses increased to $698 thousand from $150 thousand. Total assets grew modestly 3.2% to $871,958 thousand amid mixed performance across segments.

• ·Noninterest expense increased 8.1% to $18,295 thousand from $16,929 thousand.
• ·Earnings per share - basic rose to $1.81 from $1.37.
• ·Interest rate spread widened to 2.52% from 2.16%.
• ·Securities sold under repurchase agreements outstanding declined to $4,317 thousand from $5,564 thousand.

26-03-2026

Newmont Corporation's 2026 Proxy Statement reflects on a strong 2025 with record earnings, free cash flow, all-time high stock price, $1.1B returned to stockholders via dividends, completion of a $3.0B share repurchase program ($2.3B repurchased in 2025), and announcement of an additional $3.0B repurchase program. The company launched the Always Safe program achieving zero fatalities and completed an orderly CEO transition from Tom Palmer to Natascha Viljoen on January 1, 2026. Stockholders will vote on electing 12 directors, advisory approval of executive compensation, and ratification of Ernst & Young LLP as auditors at the virtual annual meeting on May 12, 2026.

• ·Annual Meeting: May 12, 2026, 8:00 a.m. Mountain Daylight Time, virtual at https://meetnow.global/MQD4CLQ
• ·Record Date: March 16, 2026
• ·Proxy materials first sent: On or about March 31, 2026

26-03-2026

This 8-K/A amends the March 5, 2026 Form 8-K for Benchmark 2026-V21 Mortgage Trust by making clerical revisions to Exhibit 4.1 (Pooling and Servicing Agreement), filing previously unavailable Exhibit 4.6 (another Pooling and Servicing Agreement), and providing an updated Exhibit 4.9 (Co-Lender Agreement for CityFoundry STL Whole Loan). No other changes were made to the original filing. The amendments include agreements dated March 1, 2026, and March 5, 2026, involving multiple servicers, trustees, and depositors.

• ·Original Form 8-K filed March 5, 2026; amendment filed March 26, 2026
• ·Exhibit 4.1 dated March 1, 2026
• ·Exhibit 4.6 dated March 1, 2026
• ·Exhibit 4.9 dated March 5, 2026

26-03-2026

VMED O2 UK Limited reported revenue of £10,113.1 million for the year ended December 31, 2025, down 5.3% YoY from £10,680.5 million, while programming costs decreased 14.5% to £3,151.2 million; however, impairments, restructuring and other operating items surged to £3,893.1 million, resulting in an operating loss of £3,246.5 million versus a £812.1 million profit in 2024. Net loss attributable to owners widened to £4,373.1 million from a £1.3 million profit, driving total assets down 12.0% to £32,767.5 million and owners' equity to £5,993.3 million from £10,430.9 million. Total liabilities remained stable near £26.8 billion.

• ·Dividends paid £378.0 million in 2025.
• ·Initial recognition of NCI in O2 Daisy £58.4 million.
• ·Excess consideration on O2 Daisy £338.9 million.
• ·Capital reduction in 2024 of £6,616.5 million.
• ·Goodwill decreased to £12,561.3 million from £15,396.8 million.

26-03-2026

Red Robin Gourmet Burgers, Inc. (RRGB) filed DEFA14A definitive additional proxy materials for its 2026 Annual Meeting scheduled for May 14, 2026, at 8:00 AM MDT in Englewood, Colorado. Key proposals include the election of seven director nominees (Anthony Ackil, Steven Lumpkin, Christopher Martin, David Pace, James Pappas, Nicole Miller Regan, and Anddria Varnado), advisory approval of named executive officers' compensation, approval of an amendment to increase authorized shares in the Amended and Restated Employee Stock Purchase Plan, and ratification of Deloitte & Touche LLP as independent auditors for the fiscal year ending December 27, 2026. Voting must be completed by May 13, 2026, 11:59 PM ET.

• ·Voting instructions available at www.ProxyVote.com or by calling 1-800-579-1639
• ·Request paper/email copies of materials by April 30, 2026
• ·Brokers may vote routine matters if instructions not received 10 days prior to meeting

26-03-2026

Liberty Broadband Corporation's DEF 14A proxy statement solicits votes for the 2026 Annual Meeting on May 11, 2026, for the election of Class III directors John C. Malone, Gregg L. Engles, and John E. Welsh III to serve until 2029, and ratification of KPMG LLP as independent auditors for the fiscal year ending December 31, 2026. The company notes its principal asset is ownership in Charter, the second-largest U.S. cable operator, and the completion of the GCI Liberty spin-off in July 2025. Governance highlights include 75% independent directors, separate Chairman and CEO roles, and strong oversight practices with no reported issues.

• ·Annual meeting held virtually on May 11, 2026 at 11:15 a.m. Mountain time via www.virtualshareholdermeeting.com/LBRD2026.
• ·Record date: March 23, 2026, 5:00 p.m. New York City time for holders of LBRDA, LBRDB, and LBRDP.
• ·2025 Form 10-K filed with SEC on February 5, 2026.
• ·Notice of proxy materials mailed on or about March 27, 2026.

26-03-2026

On March 20, 2026, H.C. Charles Diao notified Bally’s Chicago, Inc. of his resignation as Chief Financial Officer effective April 1, 2026, to pursue another professional opportunity, with no disagreements on operations, policies, or practices, and no separation agreement. On March 26, 2026, Cheryl R. Ash, age 46, was appointed as the new CFO subject to regulatory approvals; she has over 18 years of experience in the casino-hospitality industry and currently serves as Senior Vice President, Finance, Casinos and Resorts at parent Bally’s Corporation. Ms. Ash’s existing employment agreement provides an annual base salary of $328,214 and a target bonus of 75% of base salary, with no immediate changes anticipated.

• ·H.C. Charles Diao also resigning as Senior Vice President and Treasurer of Bally’s Corporation.
• ·No family relationships between Cheryl R. Ash and any director or executive officer of the Company.
• ·Cheryl R. Ash has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.
• ·Cheryl R. Ash holds a Master of Business Administration from Louisiana State University Shreveport and a Bachelor of Science in Accounting from the University of Nevada, Las Vegas.
• ·Appointment of Cheryl R. Ash subject to customary regulatory approvals; future equity grants and potential new employment agreement to be determined.

26-03-2026

On March 25, 2026, the Compensation Committee of Alight, Inc.'s Board approved performance-vesting restricted stock units (TVR Awards) under the 2021 Omnibus Plan to named executive officers Rohit Verma (7,000,000 shares) and Martin Felli (1,250,000 shares), benchmarked against peers with input from Mercer. The awards vest pro-rata based on 20-day VWAP stock price milestones ranging from $1.50-$2.25 (Tranche 1, 25%) to $3.75-$4.50 (Tranche 4, 25%) anytime from April 1, 2026, to December 31, 2030, or change in control. Vested shares generally require a 12-month hold, subject to employment conditions and exceptions for death, disability, or change in control.

• ·Vesting certified quarterly based on prior quarter's 20-day VWAP performance.
• ·Pro-rata vesting within tranches if VWAP between min/max (e.g., $1.875 VWAP yields 12.5% of total award for Tranche 1).
• ·Employment required through quarter-end for vesting (exceptions for death/disability).
• ·Measurement Period ends early on change in control, using change in control price if higher.
• ·Vested shares held 12 months post-vesting (exceptions for death, disability, estate planning, change in control).

26-03-2026

Banc of California delivered strong 2025 performance, with adjusted EPS up 69% to $1.35, total revenue increasing 12%, adjusted pre-tax pre-provision income up 39%, loan production and disbursements up 31% to $9.6B, and return on tangible common equity expanding 319 basis points to 10.75% in Q4, while repurchasing 13.6 million shares (8% outstanding) and achieving 28% TSR outperforming the KRX peer index at 7%. Credit quality improved with special mention loans at 1.83% and nonperforming loans at 0.64%. However, approximately $6B in sub-optimally priced multifamily loans and $2B in long-dated lower-yielding held-to-maturity securities remain as legacy assets expected to provide future tailwinds.

• ·2026 Annual Meeting of Stockholders: May 6, 2026, at 8:00 A.M. PDT, virtual at www.virtualshareholdermeeting.com/BANC2026.
• ·Proposals: (I) Election of ten directors; (II) Ratification of Ernst & Young LLP as independent auditors for 2026; (III) Advisory approval of named executive officer compensation (Say-on-Pay); (IV) Approval of Second Amended and Restated 2018 Omnibus Stock Incentive Plan.
• ·Record date: March 13, 2026.
• ·Annual Report on Form 10-K for year ended December 31, 2025, filed February 27, 2026.

26-03-2026

On March 23, 2026, Andalusian Credit Company, LLC entered into an Amended and Restated LLC Agreement for newly-formed Andalusian Credit Rated JV I LLC, a joint venture with Carlyle affiliates focused on middle market loan and private credit assets. The Company committed up to $52,500,000 in Class B equity interests (87.5% ownership cap) and Carlyle up to $7,500,000 in Class A, with total equity commitments of $60,000,000; the JV issued delayed draw notes totaling $140,000,000 across four classes rated by Morningstar DBRS exclusively to Carlyle. The JV is managed by a four-member board with equal designees from each party, requiring unanimous approval for material decisions.

• ·Company made initial capital contribution in kind via an initial portfolio of loans.
• ·Distributable proceeds prioritize Class A Interests over Class B.
• ·Board consists of four managers: two designated by Carlyle, two by Company.
• ·All portfolio, investment, sales, modifications, tax, and debt decisions require Board approval including at least one designee from each party.
• ·Andalusian Credit Partners, LLC engaged for administrative services.

26-03-2026

Net assets of the MetLife Policyholder Trust decreased $776 million, or 8%, to $8.4 billion at December 31, 2025 from $9.1 billion at December 31, 2024, primarily due to a $704 million decrease in net unrealized investment gains on Trust Shares and net outflows from the Purchase and Sale Program, withdrawals, and escheatment totaling $72 million. Trust Shares declined from 111,587,813 to 105,915,235, a net reduction of 5,672,578 shares, though the Trust's ownership percentage of MetLife, Inc. Common Stock remained flat at 16.2%. Dividends received totaled $245 million (up from $247 million aggregate but higher per share at $2.248 from $2.155), with $226 million in net realized gains from sales fully allocated to beneficiaries.

• ·Trust Shares net reduction: 3,363,218 from Purchase and Sale Program activity, 1,061,667 from beneficiary withdrawals, 1,247,693 from escheatment.
• ·Net unrealized investment gains decreased $704 million YoY.
• ·Trust terminable at MetLife, Inc. discretion as Trust Shares are 16.2% of outstanding Common Stock (below 25% threshold); at February 12, 2026, still 16.2%.
• ·No cybersecurity incidents materially affecting the Trust during the period.

26-03-2026

On March 22, 2026, Michael Cory Zwerling, Chief Financial Officer of RetinalGenix Technologies Inc., resigned effective immediately, with no reason provided in the filing. The departure was disclosed in an 8-K filing on March 26, 2026, signed by CEO Jerry Katzman. No successor was announced, which may introduce uncertainty in financial reporting and leadership stability.

• ·Company address: 1450 North McDowell Boulevard, Suite 150, Petaluma, CA 94954
• ·IRS Employer Identification No.: 82-3936890
• ·Emerging growth company status: Yes, elected not to use extended transition period for new accounting standards

26-03-2026

Alpha Cognition Inc. reported FY 2025 total revenue of $10.2 million, including $6.8 million in ZUNVEYL net product revenue, with Q4 net product revenue of $2.5 million and bottles dispensed up 62% QoQ to 4,941. While commercial metrics showed strong growth, including 50% QoQ increase in Q4 prescribers and execution of a second national PBM contract, operating loss widened to $22.7 million from $12.0 million in 2024 and net loss increased to $20.7 million from $14.8 million, driven by SG&A expenses rising to $29.1 million from $8.0 million. Cash position strengthened to $66.0 million at year-end, providing a runway of approximately two years.

• ·Executed second national PBM contract, now covering two of four major PBMs for long-term care.
• ·Sales team engaged approximately 4,000 unique facilities since launch.
• ·Expect two product approvals ex-US via partner CMS in Asia.
• ·Issued additional U.S. patent covering ZUNVEYL dosing regimens.
• ·Cash runway of approximately two years at forecasted operating levels post-October 2025 capital raise.

26-03-2026

Dermata Therapeutics reported 2025 financial results with cash and cash equivalents rising to $7.5 million from $3.2 million, fueled by $12.1 million in net financing proceeds, R&D expenses dropping sharply to $2.9 million from $8.2 million due to completed clinical trials, but SG&A expenses increasing to $4.8 million from $4.3 million amid marketing ramp-up, resulting in a reduced net loss of $7.6 million versus $12.3 million in 2024. The company highlighted its strategic pivot to DTC skincare under the Tome brand, with plans to launch Foundational Treatment mid-2026 and Clearing Treatment shortly after, supported by a cash runway into Q1 2027. However, the firm withdrew its XYNGARI IND application to focus on this new direction.

• ·Total assets $7,864 thousand as of Dec 31, 2025 vs. $3,534 thousand as of Dec 31, 2024.
• ·Net loss per common share $(8.16) for 2025 vs. $(80.32) for 2024.
• ·Weighted average common shares outstanding 926,192 for 2025 vs. 152,974 for 2024.
• ·XYNGARI Phase 3 STAR-1 trial met all primary endpoints but IND application withdrawn.

26-03-2026

Santander Drive Auto Receivables Trust 2022-7 filed its annual 10-K for the fiscal year ended December 31, 2025, confirming full compliance with Regulation AB servicing criteria by Santander Consumer USA Inc., Santander Bank, N.A., and Citibank, N.A., with no material noncompliance identified in attached assessments and attestations. However, owner trustee Wilmington Trust, National Association faces a civil lawsuit filed February 3, 2026, by investors alleging breaches in unrelated Tricolor Holdings, LLC ABS transactions, seeking unspecified damages; WTNA intends to defend vigorously. Many standard 10-K items omitted per General Instruction J for ABS issuers, with no financial statements or performance data reported.

• ·Lawsuit filed in Supreme Court of the State of New York, County of New York, related to alleged failures in waterfall payments, servicing transition costs, post-default duties, and custodian actions in Tricolor ABS transactions.
• ·Servicing Participants' Reports on Assessment and Attestation Reports by PricewaterhouseCoopers LLP (SC and SBNA) and KPMG LLP (Citibank, N.A.) attached as exhibits.
• ·Servicer Compliance Statements by Santander Consumer USA Inc. and Santander Bank, N.A. attached as exhibits.

26-03-2026

LeonaBio (formerly Athira Pharma) reported full year 2025 financial results with cash, cash equivalents, and investments rising 72% to $88.3 million from $51.3 million, bolstered by $90 million gross proceeds from a private placement financing with cash-exercisable warrants potentially providing up to an additional $146 million. The company acquired an exclusive global license (ex-Asia/Middle East) for lasofoxifene from Sermonix Pharmaceuticals and is on track for Phase 3 ELAINE-3 enrollment completion in 4Q 2026 (topline 2H 2027) and Phase 2 ATH-1105 initiation in 2H 2026; however, R&D expenses increased 21% to $85.6 million driven by license costs, leading to a wider net loss of $105.6 million (up 9% from $96.9 million), despite G&A expenses declining 36% to $16.7 million.

• ·Phase 3 ELAINE-3 trial protocol amended to increase sample size from 500 to up to 600 participants.
• ·Prior ELAINE-1 Phase 2: median PFS 5.6 months (vs 3.7 fulvestrant), ORR 13.3% (vs 2.9%).
• ·Prior ELAINE-2 Phase 2: median PFS ~13 months, ORR 56%, clinical benefit rate 65.5%.
• ·Total assets $92.2M as of Dec 31, 2025 (vs $58.8M 2024); net loss per share $24.70 (vs $25.19).

26-03-2026

Identiv, Inc. reported net revenue of $21,484 thousand for the year ended December 31, 2025, down 19% YoY from $26,628 thousand, with declines across all regions including a sharp 39% drop in Asia-Pacific while Americas fell 16% and Europe 5%. Gross profit surged 284% to $1,307 thousand with margin expanding to 6% from 1%, operating expenses declined 17% to $23,453 thousand driven by 28% cut in G&A, and interest income rose 272% to $5,023 thousand, narrowing net loss from continuing operations to $18,003 thousand from $25,911 thousand. However, the company posted a net loss of $18,003 thousand in 2025 after the 2024 one-time gain of $100,731 thousand from discontinued Physical Security Business sale.

• ·Santa Ana headquarters lease expires January 2028; currently subleasing 5,000 sq ft from Hirsch Secure, Inc.
• ·Sauerlach, Germany facility lease expires April 2026.
• ·Ayutthaya, Thailand manufacturing facility lease expires March 2028.
• ·Restructuring and severance expenses increased 182% to $1,524 thousand in 2025.
• ·Foreign currency net losses of $1,148 thousand in 2025 vs gains of $788 thousand in 2024.

26-03-2026

On March 23, 2026, the Executive Compensation Committee of Meritage Homes Corporation approved increases in target annual cash incentive compensation and equity awards effective January 1, 2026, for CEO Phillippe Lord ($4M cash, $6M equity), EVP & CFO Hilla Sferruzza ($1.6M cash), EVP & General Counsel Malissia Clinton ($756K cash), and EVP & Chief People Officer Javier Feliciano ($412K cash, $901.25K equity), while compensation for Executive Chairman Steven J. Hilton and EVP Austin Woffinden remains unchanged. Equity awards are split approximately 50% time-based restricted stock units and 50% performance-based shares measured by adjusted return on equity (70% weight) and three-year relative total shareholder return vs. peers (30% weight). This reflects routine executive compensation adjustments with no changes for two senior executives.

26-03-2026

Zentalis Pharmaceuticals reported FY2025 net loss of $137.1 million, an improvement from $165.8 million in FY2024, due to R&D expenses decreasing 36% to $107.3 million and G&A expenses dropping 57% to $37.7 million, though revenues declined to $0 from $67.4 million. Cash, cash equivalents, and marketable securities totaled $245.9 million as of December 31, 2025, down from $371.1 million prior year but sufficient to fund operations into late 2027. Key pipeline progress includes completed DENALI Part 2a enrollment, on track for dose confirmation and ASPENOVA Phase 3 initiation in 1H 2026, and DENALI Part 2 topline readout by year-end 2026.

• ·Working capital of $216.6 million as of December 31, 2025 (down from $333.3 million at Dec 31, 2024).
• ·Total operating expenses $152.8 million for FY2025 (down from $258.6 million in FY2024).
• ·Restructuring expenses of $7.8 million in FY2025.
• ·Net loss per common share $(1.91) for FY2025 (improved from $(2.33) in FY2024).

26-03-2026

Iridex reported strong Q4 2025 revenue of $14.7 million, up 16% YoY from $12.7 million, and full-year 2025 revenue of $52.7 million, up 8% YoY from $48.7 million, driven by 22% YoY growth in Retina products to $8.9 million in Q4 and 15% in Cyclo G6 to $3.8 million. Operating expenses fell 10% YoY in Q4 to $5.5 million and 22% full-year to $21.8 million, achieving positive adjusted EBITDA of $0.8 million in Q4 and $1.1 million full-year, with net loss improving to $0.2 million in Q4. However, gross margins declined to 37% in both Q4 and full-year due to higher manufacturing costs and inventory write-downs, cash remained low at $6.0 million, Cyclo G6 systems sales dipped to 44 units from 47 YoY in Q4, and 2026 revenue guidance of $51-53 million implies flat to 5% pro forma growth amid Middle East disruptions.

• ·2026 revenue guidance: $51-53 million (1-5% pro forma growth excluding Middle East revenue)
• ·Q4 2025 adjusted EBITDA: $0.8 million (vs $0.6 million prior year)
• ·Full year 2025 adjusted EBITDA: $1.1 million (vs -$4.3 million prior year)
• ·Cash increased $0.4 million in Q4 to $6.0 million
• ·No 2026 sales contemplated in Middle East region due to disruptions
• ·2026 adjusted operating expenses guidance: $19-19.5 million

26-03-2026

Venture Global, Inc. issued a press release on March 26, 2026, announcing a settlement agreement between its affiliate Venture Global Calcasieu Pass, LLC and Edison S.p.A., pursuant to which an affiliate of VGCP has agreed to deliver cargoes to Edison in Europe. The disclosure is made under Regulation FD (Item 7.01) and includes forward-looking statements about the settlement, potential delivery of cargoes, ongoing arbitrations, and related risks. No financial terms of the settlement were disclosed.

26-03-2026

Quoin Pharmaceuticals reported a widened net loss of $15,804,655 for the year ended December 31, 2025, compared to $8,962,472 in 2024, driven by total operating expenses rising 71% to $16,290,716 from $9,528,465, with R&D expenses surging 172% to $9,802,807 amid product development efforts. General and administrative expenses also increased 9.5% to $6,487,909. Other income declined to $486,061 from $565,993, while the company plans to commercialize QRX003 by building sales infrastructure in the U.S., Europe, and Japan, and partnering in other regions.

• ·No dividends paid or intended on ordinary shares.
• ·ADS holders may face risks in receiving dividends or distributions compared to ordinary shareholders.
• ·Regulatory approval timing for product candidates unpredictable, impacting revenue.
• ·Commercialization partners targeted for Canada, Australia/New Zealand, Middle East, China, Hong Kong, Taiwan, Latin America, Central and Eastern Europe, Turkey, and Singapore.

26-03-2026

LB Pharmaceuticals Inc. (LBRX) reported a significantly reduced net loss of $25,205 for the year ended December 31, 2025, compared to $63,102 in 2024, primarily due to a sharp 67% decline in research and development expenses to $16,744 while general and administrative expenses remained essentially flat at $13,660. The company bolstered its balance sheet through an initial public offering, raising net proceeds of approximately $302,562 via financing activities, which increased cash and cash equivalents to $250,173 and total assets to $312,934. However, it continued to report operating cash burn of $35,208 and a realized gain on sale of marketable securities declined sharply to $119.

• ·Net cash used in investing activities shifted to $(39,887) in 2025 from $23,234 provided in 2024.
• ·Accumulated deficit increased to $129,528 as of Dec 31, 2025 from $104,323.
• ·Net loss per share improved to $(3.13) from $(176.15), reflecting increased shares outstanding (weighted average 8,045,145 vs 358,229).
• ·Derivative liability decreased to $1,343 from $2,504.
• ·Audited by BDO USA, P.C. (PCAOB ID#243), New York, NY.

26-03-2026

Corebridge Financial, Inc. has entered into a definitive all-stock merger agreement with Equitable Holdings, Inc., forming a leading retirement, life, wealth, and asset management company with more than 12 million customers and $1.5 trillion in assets under management and administration. The transaction is expected to deliver enhanced scale, diversification, expanded retirement capabilities, and a modernized customer experience, while maintaining operational continuity until closing. Closure is anticipated by year-end 2026, subject to regulatory approvals, shareholder votes, and customary conditions.

• ·Filing date: March 26, 2026
• ·Merger subject to customary closing conditions including regulatory approvals and shareholder approval
• ·Companies to operate separately until closing; no changes to client contacts

26-03-2026

Apimeds Pharmaceuticals US Inc. (APUS) announced a material breach of the merger agreement by Inscobee Inc. and Apimeds Inc., who filed Amendment No. 2 to Schedule 13D on March 20, 2026, purporting to remove all four sitting directors via written consent using 6,416,365 shares subject to APUS's irrevocable proxy and install three new directors. APUS deems the actions void, lacking majority without those shares, and plans an emergency filing in Delaware Court of Chancery under 8 Del. C. § 225 for invalidation and a Temporary Restraining Order. The company has engaged Korean counsel, notified the transfer agent and NYSE American, and remains committed to the merger while pursuing remedies.

• ·Stockholder Support and Lock-Up Agreement dated December 1, 2025.
• ·Proxy granted to APUS described as 'coupled with an interest' and irrevocable.
• ·Actions violate waiver of rights to impede merger consummation.
• ·Emergency action seeks declaration under 8 Del. C. § 225.